HKG: 2348

Akeso Biopharma (HKG: 9926) is poised to acquire a 35% stake in AD Pharmaceuticals Co., Ltd., a joint venture with Dawnrays Pharmaceutical (HKG: 2348), for a total consideration of RMB 267 million (USD 37.5 million). Upon completion of the transaction, AD Pharmaceuticals will become a wholly-owned subsidiary of Akeso. AD…